N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidin-3-yl)acrylamide
99%
- Product Code: 214780
CAS:
1776112-90-3
| Molecular Weight: | 415.42 g./mol | Molecular Formula: | C₁₈H₂₂FN₉O₂ |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD29079007 | |
| Melting Point: | Boiling Point: | ||
| Density: | 1.52±0.1 g/cm3(Predicted) | Storage Condition: | 2-8°C, light-proof, inert gas |
Product Description:
Used as a potent inhibitor in targeted cancer therapies, particularly in the treatment of non-small cell lung cancer (NSCLC). It functions by selectively inhibiting mutant forms of the epidermal growth factor receptor (EGFR), including T790M and activating mutations, which are commonly associated with tumor progression and resistance to earlier-generation inhibitors. By covalently binding to the ATP-binding site of these mutant receptors, it blocks downstream signaling pathways involved in cell proliferation and survival. Its structural design allows improved selectivity for mutant EGFR over wild-type, reducing off-target effects and enhancing therapeutic efficacy. This compound is especially valuable in patients who have developed resistance to first-line EGFR inhibitors, offering a targeted option with favorable pharmacokinetic properties and central nervous system penetration, making it effective against brain metastases.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 1mg | 10-20 days | ฿3,890.00 |
+
-
|
| 5mg | 10-20 days | ฿11,660.00 |
+
-
|
| 10mg | 10-20 days | ฿19,820.00 |
+
-
|
N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidin-3-yl)acrylamide
Used as a potent inhibitor in targeted cancer therapies, particularly in the treatment of non-small cell lung cancer (NSCLC). It functions by selectively inhibiting mutant forms of the epidermal growth factor receptor (EGFR), including T790M and activating mutations, which are commonly associated with tumor progression and resistance to earlier-generation inhibitors. By covalently binding to the ATP-binding site of these mutant receptors, it blocks downstream signaling pathways involved in cell proliferation and survival. Its structural design allows improved selectivity for mutant EGFR over wild-type, reducing off-target effects and enhancing therapeutic efficacy. This compound is especially valuable in patients who have developed resistance to first-line EGFR inhibitors, offering a targeted option with favorable pharmacokinetic properties and central nervous system penetration, making it effective against brain metastases.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :